Status:
WITHDRAWN
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Breast Cancer
Breast Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- ECOG performance score of 0-2
- Signed informed consent
- Histologically confirmed AR+ breast cancer
- All participants under consideration for enrollment will have their tumor specimen tested centrally at MSK; nuclear AR staining ≥ 1% will be considered positive.
- Progressive metastatic breast cancer manifested as increase in evaluable disease OR the appearance of new sites of disease since the date of the last imaging study performed and under consideration for AR-targeted therapy
- Planning to undergo treatment with agents targeting the antiandrogen signaling pathway on a clinical trial
Exclusion
- Life expectancy \< 3 months
- Pregnancy or lactation
- Participants who cannot undergo scanning because of
- weight limits
- devices or implants that are not MRI safe
- allergies to contrast materials
- CNS only disease on recent imaging
Key Trial Info
Start Date :
October 24 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 29 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06145399
Start Date
October 24 2023
End Date
April 29 2024
Last Update
May 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.